Literature DB >> 8545055

Neuroprotection after focal cerebral ischaemia in hyperglycaemic and diabetic rats.

L Bômont1, E T MacKenzie.   

Abstract

The effects of acute hyperglycaemia and streptozotocin-induced diabetes on infarct size were measured 48 h after middle cerebral artery occlusion (MCAO) in Fischer 344 rats. Both hyperglycaemia (+46%) and diabetes (+68%) increased infarct volume when compared to normoglycaemic rats. Insulin-treated diabetic rats exhibited an infarct size similar to that observed in normoglycaemic rats. Neuroprotection has been difficult to demonstrate in pathological conditions that increase infarct volume such as chronic arterial hypertension. However, administration of the non-competitive NMDA antagonist, dizocilpine (MK-801), after MCAO, reduced the volume of ischaemic damage (by 33-48%) in all groups. The present findings indicate (a) that the detrimental effects of experimental diabetes on infarct volume are largely attributed to hyperglycaemia; and (b) dizocilpine was as neuroprotective in hyperglycaemia and diabetic conditions as in normoglycaemic rats.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8545055     DOI: 10.1016/0304-3940(95)11899-8

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  13 in total

1.  Insulin and glucagon share the same mechanism of neuroprotection in diabetic rats: role of glutamate.

Authors:  Rami Abu Fanne; Taher Nassar; Samuel N Heyman; Nuha Hijazi; Abd Al-Roof Higazi
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-06-15       Impact factor: 3.619

Review 2.  Hyperglycemia, acute ischemic stroke, and thrombolytic therapy.

Authors:  Sherif Hafez; Maha Coucha; Askiel Bruno; Susan C Fagan; Adviye Ergul
Journal:  Transl Stroke Res       Date:  2014-03-13       Impact factor: 6.829

Review 3.  Diabetic aggravation of stroke and animal models.

Authors:  Ashish K Rehni; Allen Liu; Miguel A Perez-Pinzon; Kunjan R Dave
Journal:  Exp Neurol       Date:  2017-03-06       Impact factor: 5.330

Review 4.  Considering hyperglycemia and thrombolysis in the Stroke Hyperglycemia Insulin Network Effort (SHINE) trial.

Authors:  Andrew M Southerland; Karen C Johnston
Journal:  Ann N Y Acad Sci       Date:  2012-09       Impact factor: 5.691

Review 5.  Hyperglycaemia and infarct size in animal models of middle cerebral artery occlusion: systematic review and meta-analysis.

Authors:  Niall J J MacDougall; Keith W Muir
Journal:  J Cereb Blood Flow Metab       Date:  2010-12-15       Impact factor: 6.200

6.  Diabetes mellitus, acute hyperglycemia, and ischemic stroke.

Authors:  Askiel Bruno; David Liebeskind; Qing Hao; Radoslav Raychev
Journal:  Curr Treat Options Neurol       Date:  2010-11       Impact factor: 3.598

Review 7.  The immune system in stroke: clinical challenges and their translation to experimental research.

Authors:  Craig J Smith; Catherine B Lawrence; Beatriz Rodriguez-Grande; Krisztina J Kovacs; Jesus M Pradillo; Adam Denes
Journal:  J Neuroimmune Pharmacol       Date:  2013-05-15       Impact factor: 4.147

8.  Preclinical stroke research: gains and gaps.

Authors:  David A Greenberg
Journal:  Stroke       Date:  2013-06       Impact factor: 7.914

Review 9.  Management of hyperglycemia during acute stroke.

Authors:  Askiel Bruno
Journal:  Curr Cardiol Rep       Date:  2009-01       Impact factor: 2.931

10.  Adaptive cerebral neovascularization in a model of type 2 diabetes: relevance to focal cerebral ischemia.

Authors:  Weiguo Li; Roshini Prakash; Aisha I Kelly-Cobbs; Safia Ogbi; Anna Kozak; Azza B El-Remessy; Derek A Schreihofer; Susan C Fagan; Adviye Ergul
Journal:  Diabetes       Date:  2009-10-06       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.